FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)

Published date19 November 2019
Subject MatterFDA,Biosimilars,Pharmaceutical Industry,Samsung Bioepis
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT